AZD2858

Target: This ligand targets glycogen synthase kinase 3 alpha and beta (GSK3α/GSK3β) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for glycogen synthase kinase 3 alpha and beta (GSK3α/GSK3β). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings glycogen synthase kinase 3 alpha into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated BRD4 Degradation: AZD2858 can serve as a high-affinity ligand component in PROTAC constructs targeting BRD4, enabling recruitment of an E3 ligase to trigger ubiquitination and proteasomal degradation. This application supports systematic evaluation of linker length, geometry, and ternary-complex stability to optimize degradation potency over simple inhibition.

• E3 Ligase Recruitment Optimization: Using AZD2858 in PROTAC design allows researchers to test multiple E3 ligase ligands and assess how ligase choice affects substrate engagement, ubiquitin transfer, and degradation kinetics. Such studies help map structure–activity relationships governing productive ternary complex formation and improved degradation selectivity.

• Ternary Complex Mechanism Studies: AZD2858-based PROTACs are well suited for mechanistic experiments that quantify ternary complex formation between BRD4, the PROTAC, and the recruited E3 ligase. Measuring binding cooperativity and residence time can clarify why certain constructs achieve robust degradation, guiding rational refinement of PROTAC architecture.

• Proteome-Wide Degradation Profiling: Incorporating AZD2858 into PROTACs enables targeted protein degradation workflows coupled to proteomics. Researchers can compare degradation signatures across BRD4 isoforms and related BET family members, identify off-target degradations, and correlate degradation patterns with cellular phenotypes to refine design rules for specificity.

AZD2858 is a Wnt-pathway small-molecule ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of AZD2858 is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.